1-4 of 4
Henry Brown
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical Models

Lenka Oplustil O'Connor, Stuart L. Rulten, Aaron N. Cranston, Rajesh Odedra, Henry Brown, Janneke E. Jaspers, Louise Jones, Charlotte Knights, Bastiaan Evers, Attilla Ting, Robert H. Bradbury, Marina Pajic, Sven Rottenberg, Jos Jonkers, David Rudge, Niall M.B. Martin, Keith W. Caldecott, Alan Lau, Mark J. O'Connor
Journal: Cancer Research
Series: Author Choice
Cancer Res (2016) 76 (20): 6084–6094.
https://doi.org/10.1158/0008-5472.CAN-15-3240
Published: 13 October 2016
View article titled, The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical Models
Open the PDF for The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical Models in another window
Includes: Supplementary data
Journal Articles

Abstract 4719: Targeting interdependent signaling pathways to increase the durability and magnitude of response: promising combination therapy with dual mTORC1/2 inhibitors and CDK4/6 inhibitors

Claire Crafter, Jon Curwen, Oona Delpuech, Lenka Oplustilova, Stephen Green, Henry Brown, Cath Trigwell, Sabina Cosulich
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): 4719.
https://doi.org/10.1158/1538-7445.AM2015-4719
Published: 01 August 2015
View article titled, Abstract 4719: Targeting interdependent signaling pathways to increase the durability and magnitude of response: promising combination therapy with dual mTORC1/2 inhibitors and CDK4/6 inhibitors
Journal Articles

Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models

Catherine A. Eberlein, Daniel Stetson, Aleksandra A. Markovets, Katherine J. Al-Kadhimi, Zhongwu Lai, Paul R. Fisher, Catherine B. Meador, Paula Spitzler, Eiki Ichihara, Sarah J. Ross, Miika J. Ahdesmaki, Ambar Ahmed, Laura E. Ratcliffe, Elizabeth L. Christey O'Brien, Claire H. Barnes, Henry Brown, Paul D. Smith, Jonathan R. Dry, Garry Beran, Kenneth S. Thress, Brian Dougherty, William Pao, Darren A.E. Cross
Journal: Cancer Research
Series: Author Choice
Cancer Res (2015) 75 (12): 2489–2500.
https://doi.org/10.1158/0008-5472.CAN-14-3167
Published: 14 June 2015
View article titled, Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models
Open the PDF for Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models in another window
Includes: Supplementary data
Journal Articles

Abstract 1722: Investigating resistance to AZD9291

Cath Eberlein, Laura Ratcliffe, Lucy O'Brien, Katie Al-Khadimi, Henry Brown, Paul Fisher, Daniel Stetson, Zhongwu Lai, Gayle Marshall, Claire Barnes, Kenneth Thress, Brian Dougherty, William Pao, Darren Cross
Journal: Cancer Research
Cancer Res (2014) 74 (19_Supplement): 1722.
https://doi.org/10.1158/1538-7445.AM2014-1722
Published: 01 October 2014
View article titled, Abstract 1722: Investigating resistance to AZD9291